- Product Details
- Specifications
- Data /
Performance - Product Resources
The PHASIFY™ MAX cfDNA extraction kit is designed for maximum yield of cfDNA from plasma and has demonstrated superior recovery against solid phase extraction kits.
PHASIFY™ MAX Advantages
Product Details
Product Code | Input Volume | Unit Size |
---|---|---|
1010100 | 1 mL plasma | 25x reactions |
1010200 | 2 mL plasma | 25x reactions |
Specifications
Features | Specifications |
---|---|
Applications | ddPCR, PCR, real-time PCR, NGS, other |
Sample type | Plasma |
Appropriate run time per 20 preps | ~180 mins |
Elution volume | 5µL - 150µL |
Shelf life stability | 12 months |
Intended use | Research Use Only (RUO) |
Processing | Manual |
Shipping Condition | Room Temperature |
Storage Condition |
RT Box: Stored at 15-30 °C Cold Box: Stored at 4°C |
Data / Performance
PHASIFY™ MAX cfDNA extraction kit, powered by novel PHASIFY™ technology, demonstrated 3-fold greater yields of circulating cell-free DNA (cfDNA) and circulating cell-free tumor DNA (ctDNA) in cancer patient plasma compared to the Qiagen QIAamp Circulating Nucleic Acid kit.
I. Improved yield of total DNA (cfDNA)

Figure 1 - The cfDNA was extracted from 89 tissue positive cancer patient plasma samples (1mL) using PHASIFY™ MAX and the QIAamp CNA kit. Total DNA recovery was measured using Quant-iT™ PicoGreen™ dsDNA Assay Kit. On average PHASIFY™ MAX demonstrated a 3.8-fold increase in total DNA recovery compared to QIAamp CNA (P-Value <0.0001 Wilcoxon Signed-Rank). Note, 2 outliers were excluded in which PHASIFY™ MAX generated 209-fold and 800-fold greater recovery.

Figure 1 - The cfDNA was extracted from 89 tissue positive cancer patient plasma samples (1mL) using PHASIFY™ MAX and the QIAamp CNA kit. Total DNA recovery was measured using Quant-iT™ PicoGreen™ dsDNA Assay Kit. On average PHASIFY™ MAX demonstrated a 3.8-fold increase in total DNA recovery compared to QIAamp CNA (P-Value <0.0001 Wilcoxon Signed-Rank). Note, 2 outliers were excluded in which PHASIFY™ MAX generated 209-fold and 800-fold greater recovery.
II. Improved mutation detection and clinical sensitivity
Tumor Type | PHASIFY™ MAX (MAF) | QIAamp CNA (MAF) |
---|---|---|
Pancreatic | 0.35% | ND |
Pancreatic | 0.65% | ND |
Pancreatic | 0.41% | ND |
Appendiceal | 0.35% | ND |
Ovarian | 2.80% | ND |
Ovarian | 0.44% | ND |
Colorectal | 2.10% | ND |
Colorectal | 0.24% | ND |
Colorectal | 0.27% | ND |
Colorectal | 0.25% | ND |
Colorectal | 0.50% | ND |
Colorectal | 0.35% | ND |
Colorectal | 0.58% | ND |
ND = Not Detected, MAF = Mutant allele frequency
Figure 2 - In 13 samples, mutations were detected in samples extracted with PHASIFY™ MAX, but not with QIAamp CNA.
III. Greater recovery of desired cfDNA fragments


Figure 3 - DNA was extracted from 1 mL healthy human plasma using PHASIFY™ MAX or the QIAamp Circulating Nucleic Acid kit. The extracted DNA were analyzed on Agilent Bioanalyzer 2100, where 35bp and 10,380bp peaks correspond to internal markers.


Product Resources
User Manual | PHASIFY™ MAX cfDNA Extraction Kit User Manual |
Quick Start Protocol |
a. PHASIFY™ MAX cfDNA Extraction Kit Quick Start Protocol (1mL plasma input) b.PHASIFY™ MAX cfDNA Extraction Kit Quick Start Protocol (2 mL plasma input) |
Product Catalogue | PHASIFY™ MAX cfDNA Extraction Kit Product Catalogue |
Video |
a. PHASIFY™ MAX cfDNA Extraction Kit (1 mL plasma input)Demo Video b. PHASIFY™ MAX cfDNA Extraction Kit (2 mL plasma input)Demo Video |
Safety Data Sheets (SDS) |
a. SDS Solution A2 b. SDS Solution B c. SDS Solution C d. SDS D1 e. SDS Buffer D2 f. SDS A1 g. SDS Solution D3 |
FAQs |
a. PHASIFY™ MAX cfDNA Extraction Kit FAQs (1 mL plasma input) b. PHASIFY™ MAX cfDNA Extraction Kit FAQs (2 mL plasma input) |
Product Sales and Customer Services
Email : phasify@phasesci.com | | | Contact : | Hong Kong | +(852) 3892-7211 (9am - 6pm UTC+8) |
US | +1 (657) 233-5880 (9am - 6pm Pacific) |
Contact : |
Hong Kong +(852) 3892-7211
(9am - 6pm UTC+8)
US +1 (657) 233-5880
(9am - 6pm Pacific) |